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ABSTRACT OF DISSERTATION 
 
 
 
 
IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES 
BETWEEN HUMAN FOLLICLE STIMULATING HORMONE AND THE 
FOLLICLE STIMULATING HORMONE RECEPTOR 
 
 Follicle stimulating hormone (FSH) comprises an α subunit and a β subunit, 
whereas the FSH receptor consists of two halves with distinct functions, the N-terminal 
extracellular exodomain and C-terminal membrane associated endodomain.  FSH initially 
binds to exodomain, and the resulting FSH/exodomain complex modulates the endodomain 
and generates signal.  However, it has been difficult to determine which subunit of FSH 
contacts the exodomain or endodomain, and in what orientation FSH interacts with them.  
To address these crucial issues, the receptor was Ala-scanned and the hormone subunits 
were probed with photoaffinity labeling with receptor peptides corresponding to the N-
terminal region of the exodomain and exoloop 3 of the endodomain.  The results show that 
both regions of the receptors are important for hormone binding and signal generation.  In 
addition, the FSH β subunit is specifically labeled with the N-terminal peptide, whereas the 
α subunit is labeled with the exoloop 3 peptide.  These contrasting results show that the FSH 
β subunit is close to the N-terminal region and the α subunit is projected toward exoloop 3 
in the endodomain.  The results raise the fundamental question whether the α subunit, 
common among the glycoprotein hormones, plays a major role in generating the hormone 
signal common to all glycoprotein hormones. 
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Chapter 1   Introduction 
 
Gonadotropins 
 
  Follicle-stimulating hormone (FSH), luteinizing hormone (LH), and chorionic 
gonadotropin (CG) are gonadotropins (Bousfield et al., 1996). These hormones belong to the 
family of glycoprotein hormones which also includes thyroid-stimulating hormone (TSH) 
(Pierce and Parson, 1981). The gonadotropins are produced by different tissues: FSH and LH 
of pituitary origin; CG of placental origin (Pierce and Parson, 1981). 
FSH has been found in animals as a key hormonal molecule playing a central role in 
the regulation of mammalian reproduction. In females, it is essential to promote and sustain 
ovarian and follicular development and maturation since early development stages, whereas 
in males it regulates spermatogenesis (Adashi, 1996; Hsueh et al., 1983). FSH binds 
specifically to follicle-stimulating hormone receptors (FSHR) on granulosa cells in the ovary 
or Sertoli cells in the testis and stimulates the aromatase system that catalyzes the conversion 
of androgens into estrogens (Adashi, 1996). 
LH is also a key molecule for reproduction. The function of LH is the initiation of 
steroidogenesis in the thecal cells of the follicle and the Leydig cells of the testis. This 
glycoprotein hormone also induces the ovulation and luteinization of fully developed follicles. 
LH and FSH have synergistic effects on estrogen synthesis in the ovary, due to the fact that 
FSH promotes the production of estrogens from androgens.  LH is involved in maintaining 
corpus luteum progesterone production, although this role appears to vary among species.  In 
males, LH triggers the synthesis of androgens needed for spermatogenesis and the 
development of secondary sexual characteristics. (Catt et al., 1980; Filicori, 1999; Richards et 
al., 1995).  
 2 
It is evident that physiologic growth and maturation in reproduction is dependent on 
the dynamic interplay between both gonadotropins; key physiologic events rely on both the 
prevalence of either FSH or LH activity. 
CG is closely related in structure and activity to LH, since CG and LH bind to the 
same receptor, LH/CG receptor. CG plays an important role for maintaining pregnancy in 
animals.  Secretion of human chorionic gonadotropin (hCG) from placenta begins at about 
the time of implantation and reaches peak levels during the first trimester (Cameo et al., 
2004; Keay et al., 2004).  hCG serves as a signal to the ovary to maintain the corpus luteum 
thus prolonging luteal progesterone synthesis.  hCG binds to LH/CG receptors expressed on 
the surface of luteal cells and granulosa cells, resulting in the activation of adenylyl cyclase 
and production of intracellular cAMP (Menon and Kiburz, 1974). In the absence of hCG, the 
decline in maternal LH due to inhibition of the pituitary by progesterone would result in 
menstruation and spontaneous abortion of the embryo (Keay et al., 2004). 
 
Structurally, each of the gonadotropins is comprised of two subunits, a common alpha 
subunit and a hormone-specific beta subunit. The alpha subunit consists of 92 amino acids 
and the composition of the beta subunit varies from hormone to hormone (FSH: 111 a.a., LH: 
121 a.a., CG: 145 a.a., respectively.). The beta subunits share considerable structural 
homology and are thought to have evolved from a common precursor (Pierce and Parson, 
1981).  
 
The 9.4 kb human α subunit gene on chromosome 6q is composed of four exons, 
which encodes a 92 amino acid protein (Fiddes and Goodman, 1981), and the 10 kb human 
FSH β gene localized to chromosome 11p, contains three exons and encodes a 111 amino 
acid subunit (Jameson et al., 1988) (Figure 1.1). Each subunit contains two glycosylation 
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sites: at Asn52 and Asn78 in the α subunit and at conserved sites in the β subunit, Asn7 and 
Asn24 in human FSH (hFSH) (Gharib et al., 1990). Only the αβ dimer is capable of high 
affinity binding to receptors and inducing biological effects. The dissociated subunits lose 
high affinity binding activity (Roche and Ryan, 1985).  Both of the αβ subunits of FSH 
interact with its receptor.   
 
 
 
The Follicle-Stimulating hormone (FSH) Receptor 
 
The follicle-stimulating hormone receptor (FSHR) belongs to a subfamily of 
glycoprotein hormone receptors within the G-protein coupled receptor family (Ji et al., 1998).  
FSHR is composed of two halves of ~350 amino acids, the extracellular N-terminal 
exodomain and membrane anchored C-terminal endodomain that includes 7 transmembrane 
helices and cytotail (Loosfelt et al., 1989; McFarland et al., 1989; Sprengel et al., 1990) 
(Figure 1.2). Glycoprotein hormones initially bind to the exodomain, and then the resulting 
hormone/exodomain complex modulates the endodomain (Ji et al., 1995b), which activates 
adenylyl cyclase (AC) to generate cAMP and phospholipase Cβ (PLCβ) to produce inositol 
phosphate and diacylglycerol (Figure 1.3). Thus, the orchestrated interactions among the 
hormone, exodomain and endodomain are critical for successful signal transduction. Little 
mechanisms on the subject, particularly concerning the FSH receptor, have been 
demonstrated to explain the receptor activation. 
The exodomain is important for binding the hormone with high affinity (Ji and Ji, 
1991; Tsai-Morris et al., 1990; Xie et al., 1990) without hormone action (Ji and Ji, 1991; 
Remy et al., 1993). The exodomain and hormone complex undergoes a conformational 
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change and is thought to modulate the endodomain (Ji et al., 1995a), thus generating a signal. 
The high affinity interaction of the exodomain and FSH is the essential first step guiding to 
signal transduction and hormone action. Regardless of the importance of this initial binding 
event, only restricted information is available concerning the particular contact sites in the 
exodomain as well as the hormone.  
The exodomain consists of 8 - 9 Leu rich repeats (Bhowmick et al., 1996; Koo et al., 
1991; McFarland et al., 1989), which make up the bulk of the exodomain and are flanked by 
a short N-terminal Cysteine cluster and a C-terminal hinge region (Zeng et al., 2001).  These 
Leu rich repeats are commonly thought to construct a concave structure (Jiang et al., 1995) 
(Figure 1.2).   
Although the Leu rich repeats interact with the hormone(Song et al., 2001a), it has 
been suggested that the short N-terminal region flanking the primary hormone binding Leu 
rich repeats is crucial for FSH binding (Dias et al., 1998).  This region contains sites which 
appear critical for not only hormone binding but receptor trafficking as well (Nechamen and 
Dias, 2000).  Moreover, it has been shown that accessibility of the N-terminal residues 15-44 
is decreased upon binding (Schmidt et al., 2001).  Such an important hormone contact site 
outside of the Leu rich repeats could provide new insights of FSH-receptor interaction and 
signal generation.  In fact, a similar site has been identified in the N-terminal region of LHR 
(Hong et al., 1998; Phang et al., 1998).  Although there is little sequence homology in the N-
terminal regions of FSHR and LHR, the conservation of a Cysteine cluster suggests a 
comparable role in receptor binding, albeit with differential specificity. 
In addition, it has been reported that FSH and hCG binding to their cognate receptors 
is modulated by certain amino acid residues of exoloops 2 and 3 of the endodomain (Ryu et 
al., 1998a; Ryu et al., 1998b).  Moreover, the hinge region of the exodomain has been shown 
to interact with exoloop 2 of the endodomain and modulates cAMP induction (Nakabayashi 
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et al., 2000; Nishi et al., 2002; Zeng et al., 2001).  These results suggest that there is the 
interaction and modulation between the exodomain and the exoloops of the endodomain and 
it is required for signal generation. Nevertheless, there is no experimental evidence whether 
the hormone complexed with the exodomain also contacts the exoloops. 
 
 
 
Goal of Dissertation 
  
Sixteen percent of the human population are infertile, affecting 80 million people 
worldwide with 5 million in the United States alone (Forti and Krausz, 1998; Page, 1989). 
The receptor and hormone could potentially be used as fertility drugs as well as 
contraceptives. Current contraceptives are steroid and have serious side effects since steroids 
can affect most of body cells. In contrast, gonadotropin receptors are found primarily in the 
reproductive organs.  Therefore, the drugs based on gonadotropins will have a higher 
specificity and less side effects.  The hormone-receptor interactions generate signals and 
induce the hormone action, so it is essential to identify the contact points between hormone 
and receptor. Further understanding of the hormone and receptor interactions will provide 
new insights in targeting drug design and understanding the basic mechanism of GPCR 
activation. 
The goal of this dissertation work is to further describe the contact sites between FSH 
and the FSH receptor. FSH initially binds to exodomain, and the resulting FSH/exodomain 
complex modulates the endodomain and generates signal. However, it has been difficult to 
determine which subunit of FSH contacts the exodomain or endodomain and in what 
orientation FSH interacts with them. Photoaffinity labeling studies examine the contribution 
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of N-terminal and exoloop 3 of receptor to hormone binding. These results provide new 
insights into the mechanism of hormone/exodomain/endodomain interaction.   
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Figure 1.1  Crystal structure of FSH.  
FSH is a heterodimer composed by two different subunits: α and β. The FSH α subunit (92 
amino acids) is common to all gonadotropins (shown in red), and the FSH β subunit (111 
amino acids) is specific for FSH (shown in green). 
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Figure 1.2 Structure of the FSH receptor.  
A schematic drawing of FSHR with two distinct domains, exodomain and endodomain. The 
N-terminal exodomain consists of ~350 amino acids and binds to hormone with high affinity. 
An equal-sized endodomain is membrane-associated and is responsible for signal generation. 
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Figure 1.3 Model of signal transduction pathways of the FSH receptor.  
FSH initially binds to the exodomain, and then the resulting hormone/exodomain complex 
modulates the endodomain, which activates adenylyl cyclase (AC) to generate cAMP and 
phospholipase Cβ (PLCβ) to produce inositol phosphate and diacylglycerol. 
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Chapter 2 Interaction of Follicle-stimulating Hormone with Exoloop 3 of the FSHR 
 
INTRODUCTION 
 The follicle-stimulating hormone receptor (FSHR) and other glycoprotein hormone 
(LH/CG and TSH) receptors belong to a structurally unique subfamily of G protein-coupled 
receptors.  Unlike other receptor subfamilies, they comprise two equal halves, an N-terminal 
extracellular half (exodomain) and a C-terminal membrane associated half (endodomain) 
(Loosfelt et al., 1989; McFarland et al., 1989; Nagayama et al., 1989; Sprengel et al., 1990).  
The exodomain is ~350 amino acids long and alone is capable of high affinity hormone binding 
(Davis et al., 1995; Ji and Ji, 1991; Tsai-Morris et al., 1990; Xie et al., 1990) with hormone 
selectivity (Braun et al., 1991; Liu et al., 1994; Moyle et al., 1994) but without hormone action 
(Ji and Ji, 1991) (Remy et al., 1993).  Receptor activation occurs in the endodomain (Ji et al., 
1995b) which is structurally equivalent to the entire molecule of many other G protein-coupled 
receptors (Probst et al., 1992).  Glycoprotein hormones initially bind to the exodomain, and 
then the resulting hormone/exodomain complex modulates the endodomain (Ji et al., 1995b), 
which activates adenylyl cyclase (AC) to generate cAMP and phospholipase Cβ (PLCβ) to 
produce inositol phosphate and diacylglycerol.  Therefore, the ternary interactions among the 
hormone, exodomain and endodomain are crucial for successful signal generation.  However, 
there is little information on the subject, particularly concerning the FSH receptor.  Since the 
exodomain lacking the endodomain is capable of high affinity hormone binding (Davis et al., 
1995; Ji and Ji, 1991; Ryu et al., 1998a; Tsai-Morris et al., 1990; Xie et al., 1990), the high 
affinity hormone binding appears to be independent of the endodomain.  Contrary to this view, 
it has been reported that FSH and hCG binding to their cognate receptors is regulated by certain 
residues of exoloops 2 and 3 of the endodomain (Ryu et al., 1998a; Ryu et al., 1998b).  
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Furthermore, the hinge region of the exodomain interacts with exoloop 2 and modulates cAMP 
induction (Nakabayashi et al., 2000; Nishi et al., 2002; Zeng et al., 2001).  These results suggest 
that the exodomain interacts with the exoloops and modulates them for signal generation.  Yet, 
it is unclear whether the hormone complexed with the exodomain also contacts the exoloops. 
 In this study, I set out to investigate whether exoloops interact with the hormone at all.  
In a step toward this goal, I examined exoloop 3 of FSHR for its involvement in the  interaction 
with FSH.  It is the shortest of the 3 exoloops, consisting of 11 amino acids (Figure 2.1), and 
has been implicated in the cAMP signal generation (Angelova et al., 2002; Ryu et al., 1998a; 
Ryu et al., 1996).  These observations show, for the first time, the interaction of exoloop 3 with 
FSH, in particular the FSH α subunit, the mode of this interactions (Sohn et al., 2002). 
 
EXPERIMENTAL PROCEDURES 
Materials 
Human FSH was purchased from the National Hormone and Pituitary Program. 
Denatured FSH was prepared by boiling the hormone in 8 M urea for 30 min. 
 
Derivatization and radioiodination of peptide 
A peptide mimic corresponding to the exoloop 3 sequence of K580VPLITVSKAK590 
(FSHRexo3) was synthesized, to which a Tyr residue was attached to the C-terminus for 
radioiodination.  The N-terminus of the peptide was acetylated and the C-terminus amidated.  
NHS-ABG was synthesized as previously described (Ji and Ji, 1981) and freshly dissolved 
in dimethyl sulfoxide to a concentration of 50 mM and NHS-ABG in 0.1 M sodium 
 12 
phosphate (pH 7.5) to a concentration of 20 mM.  These reagent solutions were immediately 
used to derivatize receptor peptides.  In the dark, 10 µl of NHS-ABG was added to 30 µg of 
receptor peptides in 40 µl of 0.1 M sodium phosphate (pH 7.5).  The mixture was incubated 
with NHS-ABG for 30 min at 25˚ C.  The following were added to the derivatization 
mixture: 1 mCi of Na125I-iodine in 10 µl of 0.1 M NaOH and 7 µl of chloramine-T (1 
mg/ml) in 10 mM Na2HPO4, pH 7.4.  After 20 sec, 7 µl of sodium metabisulfite (2.5 mg/ml) 
in 10 mM Na2HPO4, pH 7.4, was introduced to terminate radioiodination.  Derivatized and 
radioiodinated ABG-125I-FSHRexo3 solution was mixed with 60 µl of 16% sucrose solution 
in PBS and fractionated on Sephadex Superfine G-10 column (0.6 X 15 cm) using PBS.  
 
Photoaffinity labeling of FSH 
 The following solutions were sequentially introduced to siliconized glass tubes: 20 
µl of 0.9% NaCl and10 mM Na2HPO4, pH 7.4 (PBS), 10 µl of FSH (10 ng/µl) in PBS, and 
10 µl of ABG-125I-FSHR9-38 or 125I-FSHRBpa13 (10 ng/µl) in PBS.  Competitive inhibition 
experiments were carried out as described for the photoaffinity labeling experiments, except 
that 10 µl instead of 20 µl of PBS was introduced to each tube and the mixture was 
incubated with 10 µl of increasing concentrations of nonradioactive receptor peptides.  The 
mixtures were incubated at 37˚ C for 90 min in the dark, irradiated with Mineralight R-52 
UV lamp for 3 minutes as previously described (Ji and Ji, 1980), and solubilized in 2% SDS, 
100 mM dithiothreitol and 8 M urea.  The samples were electrophoresed on 8-12% 
polyacrylamide gradient gels.  Gels were dried on filter paper and exposed to an imaging 
screen overnight, which was scanned on a phosphoimager. 
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125I-FSH Binding assay 
wtFSHR cDNAs were prepared in the pSELECT vector, sequenced on a Beckman 
CEQ 2000XL capillary sequencer, subcloned into pcDNA3 (Invitrogen) as described 
previously (Ji and Ji, 1993). Wild type receptor constructs were transfected into HEK 293 
cells by the calcium phosphate method as described previously (Ji and Ji, 1993). Stable cell 
lines were established in minimum essential medium containing 10% horse serum and 500 
µg/ml G418. These cells were used for hormone-binding. All of the assays were carried out in 
duplicate and repeated 4–5 times, and the means ± S.D. were calculated. wtFSHR-expressing 
stable cells were assayed for 125I-FSH binding in the presence of 100,000 cpm of 125I-FSH (Ji 
and Ji, 1981) and increasing concentrations of unlabeled FSH or exoloop 3 peptide. 
 
Deglycosylation 
The FSH α and β subunits co-migrate on SDS-PAGE.  To separate them on the gel 
FSH was deglycosylated with PNGase F before and after it was photoaffinity labeled.  
Enzymatic cleavage was done by incubation of the labeled FSH complex with 20 or 50 units 
of PNGase F (New England BioLabs, Inc., MA) in 40 µl for 18 h at 37˚ C.  The samples 
were solubilized in SDS under the reducing condition and electrophoresed on 15 % gel 
containing 9 M urea. 
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RESULTS 
 
Photoaffinity labeling of FSH with exoloop 3 peptide 
 
 
To test the possible interaction of exoloop 3 with the hormone, 125I-ABG-FSHRexo3 was 
incubated with FSH and irradiated with UV for increasing time periods. Samples were 
solubilized in SDS under the reducing condition and electrophoresed. The autoradiographic 
phosphorimage of the gel (Figure 2.2.A) revealed the labeling of the FSH band. The two 
subunits of the human FSH preparation comigrate on SDS-PAGE. The band was not labeled 
when the sample was not irradiated with UV, suggesting the requirement for UV irradiation. 
The extent of the labeling was dependent on the irradiation time, reaching the maximum after 
60 s of irradiation. The results show that the labeling is saturable. 
To determine the nature of the labeling, increasing concentrations of the hormone 
were labeled with a constant amount of 125I-ABG-FSHRexo3 (Figure 2.2.B). Conversely, 
increasing concentrations of 125I-ABG-FSHRexo3 were used to label a constant amount of 
FSH (Figure 2.2.C). The labeling plateaued under both conditions, indicating saturable 
labeling. To examine the relationship of the labeling with other exoloops and receptor peptide, 
FSH was incubated with 125I-ABG-FSHRexo3 in the presence of increasing concentrations of 
unlabeled FSHR peptides corresponding to exoloops 1, 2, and 3 as well as the N-terminal 
sequence Ser9-Lys40, FSHR9-40, which is known to interact with FSH. Increasing 
concentrations of the peptides inhibited the photoaffinity labeling in a dose-dependent manner 
and eventually blocked the labeling with varying affinity (Figure 2.3), suggesting a specificity. 
FSHRexo2 is the most potent inhibitor, suggesting the possibility of its strong interaction with 
the hormone. Furthermore, 125I-ABG-FSHRexo3 failed to label denatured FSH that does not 
bind to the receptor, despite high concentrations of the peptide (Figure 2.4.A), suggesting the 
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specificity of the affinity labeling for biologically active FSH. FSH was denatured by boiling 
in 8 M urea for 30 min. To test whether the denatured FSH remained in solution, the mixture 
of radioactively labeled FSH and unlabeled FSH was denatured, varying volumes of the 
mixture were transferred to other tubes, and the radioactivity was counted. The transfer was 
quantitative with a 99-100 % efficiency, indicating that denatured FSH was present in the 
photoaffinity labeling tube. 125I-ABG-FSHRexo3 did not label urokinase, nor did it label 
phospholipases A, C, and D (Figure 2.4.B). In addition, it failed to noticeably label human 
growth hormone (Figure 2.4.B). The exoloop 3 peptide inhibited 125I-FSH binding to the 
receptor on intact cells in a dose-dependent manner. These results show that the binding to 
and labeling of FSH by the peptide were specific to bioactive FSH. 
 
Since the α and β subunits of human FSH comigrate on SDS-PAGE, it is unclear 
which of the subunits was labeled.  To determine the identity of the labeled subunit(s), FSH 
was labeled with 125I-ABG-FSHRexo3, deglycosylated with PNGase F, and electrophoresed.  
The labeled band corresponded to the α subunit (Figure 2.4.B).  Deglycosylated human FSH 
separates into two bands on SDS-PAGE, the higher molecular weight β subunit in the upper 
band and the smaller α subunit in the lower band, which was verified by monoclonal anti 
subunit antibodies (Sohn et al., 2003) as shown in Figure 3.9.  
 
 
DISCUSSION 
 
 In conclusion, our observations in this study show the interaction of the FSHR exoloop 
3 with FSH, specifically the α subunit.  This is consistent with the decade long view that the 
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common α subunit of the glycoprotein hormones is likely to induce the common hormone 
action, including cAMP induction (Pierce and Parson, 1981).    
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Figure 2.1   Sequence alignment of exoloop 3.  
The exoloop 3 sequences of FSHR, luteinizing hormone receptor, and thyroid-stimulating 
hormone receptor were aligned among species. Identical residues are presented as dashed 
lines. LHR, luteinizing hormone receptor; TSHR, thyroid-stimulating hormone receptor.  
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Figure 2.2   Autoradiograph of photoaffinity-labeled FSH. 
The peptide corresponding to the FSHR exoloop 3 sequence (FSHRexo3) was synthesized, 
derivatized with NHS-ABG, and radioiodinated to produce 125I-AB-FSHRexo3. As shown in A, 
FSH was incubated with 125I-AB-FSHRexo3 and irradiated with UV for increasing periods of 
time. The samples were solubilized in SDS under the reducing conditions and 
electrophoresed as described under "Experimental Procedures." After electrophoresis, the gel 
was dried and autoradiographed using phosphorimaging device. The intensity of each band in 
a gel lane was measured, and the percentage of the labeled FSH band in a gel lane was 
calculated based on the total intensity of a gel lane and presented in the bar graph. As shown 
in B, increasing concentrations of FSH were incubated with a constant amount of 125I-AB-
FSHRexo3 and irradiated with UV for 90 s. As shown in C, increasing concentrations of 125I-
AB-FSHRexo3 were incubated with a constant amount of FSH and irradiated with UV for 90 s.  
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Figure 2.3   Competitive inhibition of photoaffinity labeling.  
FSH was photoaffinity-labeled with 125I-AB-FSHRexo3, as described in the legend for Figure 
2.2, in the presence of increasing concentrations of unlabeled competitor peptides, exoloop 
1 peptide (A), exoloop 2 peptide (B), exoloop 3 peptide (C), and FSHR9-40 (D).  
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Figure 2.4   Identification of the labeled FSH subunit and futile labeling of denatured 
FSH.  
As shown in panel A, denatured FSH that is not capable of binding and activating FSHR was 
labeled with increasing concentrations of 125I-AB-FSHRexo3 as described in the legend for 
Figure 2.2. As shown in panel B, 125I-AB-FSHRexo3 was used to photoaffinity-label FSH 
(lane 1), phospholipase A (lane 2), phospholipase C (lane 3), phospholipase D (lane 4), 
urokinase (lane 5), and human growth hormone (lane 6). As shown in panel C, inhibition of 
125I-FSH binding to the receptor on intact cells in the presence of unlabeled FSH (black 
square) and exoloop 3 peptide (open square). As shown in panel D, FSH was photoaffinity-
labeled with 125I-AB-FSHRexo3, treated with PNGase F to deglycosylate it, and 
electrophoresed as described under "Experimental Procedures." The FSH α and β subunits 
separated in the lower band and upper band, respectively. 
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Chapter 3  Orientation of Follicle-stimulating Hormone (FSH) Subunits Complexed with 
the FSH Receptor : Beta-Subunit Toward The N-Terminus of Exodomain And Alpha-
Subunit to Exoloop 3. 
 
 
 
INTRODUCTION 
 
 
Follicle-stimulating hormone (FSH) consists of an α subunit of 92 amino acids and β 
subunit of 111 amino acids. Both of the subunits are necessary for hormone action (Jackson et 
al., 1999; Narayan et al., 2002). The crystal structure of human FSH (Fox et al., 2001) shows 
that the two subunits are tightly associated in a crescent with the C termini in the concave side 
and the N termini in the convex side (Figure 3.1). This is essentially the same as the human 
chorionic gonadotropin structure (Lapthorn et al., 1994; Wu et al., 1994). An exception to this 
intermingled subunit structure is the two polarized tips of the crescent: the α tip consisting of 
the α loops 1 and 3 and the β tip of the β loops 1 and 3. 
 
In contrast to the tightly held hormone structure, the FSH receptor (FSHR), a G 
protein-coupled receptor, has two distinct domains as shown in Figure 3.1.B. The 
extracellular N-terminal exodomain comprises ~350 amino acids, and the membrane-
associated C-terminal endodomain with a similar number of amino acids consists of seven 
transmembrane helices, three exoloops, three cytoloops, and the C-terminal cytoplasmic tail 
(Loosfelt et al., 1989; McFarland et al., 1989; Sprengel et al., 1990). The exodomain binds 
the hormone with high affinity (Ascoli et al., 2002; Babu et al., 1999; Davis et al., 1995; Ji 
and Ji, 1991; Schmidt et al., 2001; Seetharamaiah et al., 1994; Tsai-Morris et al., 1990; Xie et 
al., 1990) and selectivity (Vischer et al., 2003), whereas the hormone signal is generated in 
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the endodomain (Angelova et al., 2002; Ji et al., 1995b; Nishi et al., 2002; Tao et al., 2002; 
Zeng et al., 2001). FSH initially interacts with the exodomain, and the resulting 
FSH/exodomain complex modulates the endodomain to generate hormone signal. Important 
amino acids have been identified for the interaction of the hormone and receptor (Dias et al., 
1998; Osuga et al., 1997). However, the orientation of FSH α and β in the ternary complex of 
the hormone, exodomain, and endodomain has been a major enigma and difficult to 
determine.  
The bulk of the exodomain comprises 8–9 Leu-rich repeats (LRR) (Bhowmick et al., 
1996; Couture et al., 1996; Jiang et al., 1995; Koo et al., 1991; McFarland et al., 1989), which 
are flanked by the short upstream N-terminal region and the downstream hinge region. LRRs 
are thought to form a one-third of a doughnut structure (Bhowmick et al., 1996; Couture et 
al., 1996; Jiang et al., 1995). FSH appears to interact with LRRs (Dias et al., 1998; Song et 
al., 2001b) and the N-terminal and hinge regions (Nakabayashi et al., 2000; Zeng et al., 
2001). However, it is unclear which subunit of FSH contacts the exodomain or endodomain 
and in what orientation FSH interacts with them, although the concave C-terminal side of 
FSH appears to interact with the receptor. For example, FSH may interact horizontally or 
vertically with LRRs (Figure 3.1, C and D) and in two directions. These are crucial pieces of 
information for understanding the interactions among the hormone, exodomain, and 
endodomain and the mechanistics of signal generation. In addition, the information will 
facilitate the design of agonists and antagonists and development of new therapeutics. 
Because of the importance, the interactions of glycoprotein hormones with their receptors 
have been modeled (Bhowmick et al., 1996; Dias et al., 1998; Fox et al., 2001; Lapthorn et 
al., 1994; Wu et al., 1994) based on the crystal structure of the LRRs of ribonuclease inhibitor 
complexed with its ligand (Kobe and Deisenhofer, 1995). However, the evidence has been 
elusive.  
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In a step to resolve this issue, I set out to distinguish the interactions of the FSH 
subunits with the N-terminal region of the exodomain and exoloop 3 in the endodomain. My 
results show the interaction of FSH β with the N-terminal region of the exodomain and the α 
tip of FSH α with exoloop 3 (Figure 3.1.E) (Sohn et al., 2003). 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials 
Human FSH was purchased from the National Hormone and Pituitary Program. 
Denatured FSH was prepared by boiling the hormone in 8 M urea for 30 min. Rabbit anti-
FSH α serum, rabbit anti-FSH β serum, and monoclonal anti-FSHR 106.105 antibody were 
kindly provided by Dr. James Dias. Anti-rabbit IgG conjugated with peroxidase was 
purchased from Pierce. Peptide mimics including wild type peptides corresponding to the 
Ser9-Lys40 sequence (FSHR9–40) and exoloop 3 and a photoactivable peptide containing 
benzoyl phenylalanine (Bpa) in place of Phe13 (FSHR9–40F13Bpa) were synthesized by 
Genemed Synthesis (San Francisco, CA) and purified on a Vydac C18 high pressure liquid 
chromatography column using solvent gradient from 100% of 0.1% trifluoroacetic acid in 
water to 20% of 0.1% trifluoroacetic acid in water and 80% 1-propanol.  
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Mutagenesis and Functional Expression of FSH Receptors 
Mutant FSHR cDNAs were prepared in the pSELECT vector using the Altered Sites 
mutagenesis system (Promega), sequenced on a Beckman CEQ 2000XL capillary sequencer, 
subcloned into pcDNA3 (Invitrogen) as described previously (Ji and Ji, 1993), and sequenced 
again to verify mutation sequences. This procedure does not involve polymerase chain 
reaction and therefore does not have its infidelity problems. Wild type and mutant receptor 
constructs were transfected into HEK 293 cells by the calcium phosphate method as described 
previously (Ji and Ji, 1993). Stable cell lines were established in minimum essential medium 
containing 10% horse serum and 500 µg/ml G418. These cells were used for hormone-
binding and cAMP production. All of the assays were carried out in duplicate and repeated 4–
5 times, and the means ± S.D. were calculated. 
 
125I-FSH Binding and Intracellular cAMP Assay 
Stable cell lines were assayed for 125I-FSH binding in the presence of 100,000 cpm of 
125I-FSH (Ji and Ji, 1981) and increasing concentrations of unlabeled FSH. The Kd values 
were determined by Scatchard plots. For intracellular cAMP assay, cells were washed twice 
with Dulbecco's modified Eagle's medium and incubated in the medium containing 0.1 µg/ml 
isobutylmethylxanthine for 15 min. Increasing concentrations of FSH were then added, and 
incubation was continued for 45 min at 37 °C. After removing the medium, the cells were 
rinsed once with fresh medium without isobutylmethylxanthine, lysed in 70% ethanol, freeze-
thawed in liquid nitrogen, and scraped. After pelleting cell debris at 16,000 x g for 10 min at 4 
°C, the supernatant was collected, dried under vacuum, and resuspended in 10 µl of cAMP 
assay buffer (Amersham Biosciences). cAMP concentrations were determined with an 125I-
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cAMP assay kit (Amersham Biosciences) following the manufacturer's instructions and 
validated for use in our laboratory.  
 
 
125I-FSH Binding to Solubilized FSHR 
Transfected cells were washed twice with ice-cold 150 mM NaCl, 20 mM HEPES, pH 
7.4 (buffer A). Cells were scraped on ice, collected in buffer A containing protease inhibitors 
(1 mM phenylmethylsulfonyl fluoride, 5 mM N-ethylmaleimide, and 10 mM EDTA), and 
pelleted by centrifugation at 1300 x g for 10 min. Cells were resuspended in 0.6 ml of buffer 
A containing 1% Nonidet P-40, 20% glycerol, and the above protease inhibitors (buffer B), 
incubated on ice for 15 min, and diluted with 5.4 ml of buffer A containing 20% glycerol plus 
the protease inhibitors (buffer C). The mixture was centrifuged at 100,000 x g for 60 min. The 
supernatant (500 µl) was mixed with 100,000 cpm of 125I-FSH and 6.5 µl of 0.9% NaCl and 
10 mM Na2HPO4 at pH 7.4 containing increasing concentrations of unlabeled FSH. After 
incubation for 12 h at 4 °C, the solution was thoroughly mixed with 250 µl of buffer A 
containing bovine -globulin (5 µg/ml) and 750 µl of buffer A containing 20% polyethylene 
glycol 8000. After incubation for 10 min at 4 °C, samples were pelleted at 1,300 x g for 30 
min and supernatants removed. Pellets were resuspended in 1.5 ml of buffer A containing 
20% polyethylene glycol 8000, centrifuged, and counted for radioactivity. Monoclonal anti-
FSHR antibodies were radioiodinated and used for binding to nonbinding mutant FSHRs 
expressed on the intact cell surface as described previously (Hong et al., 1998).  
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Derivatization and Radioiodination of Peptides 
In the dark, 30 µg of receptor peptides in 40 µl of 0.1 M sodium phosphate, pH 7.5, 
was mixed with 1 mCi of Na-[125I]iodine in 10 µl of 0.1 M NaOH and 7 µl of chloramine-T (1 
mg/ml) in 10 mM Na2HPO4, pH 7.4. After 20 s, 7 µl of sodium metabisulfite (2.5 mg/ml) in 
10 mM Na2HPO4, pH 7.4, was introduced to terminate radioiodination. Radioiodinated 
peptides were mixed with 60 µl of 16% sucrose solution in PBS and fractionated on Sephadex 
Superfine G-10 column (0.6 x 15 cm) using PBS. Peptides were derivatized with 4-
azidobenzoyl glycine (ABG) and radioiodinated as described previously (Sohn et al., 2002).  
 
Photoaffinity Labeling of FSH 
The following solutions were sequentially introduced to siliconized glass tubes: 20 µl 
of 0.9% NaCl and 10 mM Na2HPO4, pH 7.4, in PBS, 10 µl of FSH in PBS, and 10 µl of 125I-
FSHR9–40F13Bpa in PBS. Competitive inhibition experiments were carried out as described for 
the photoaffinity-labeling experiments with the exception that 10 µl instead of 20 µl of PBS 
was introduced to each tube and the mixture was incubated with 10 µl of increasing 
concentrations of nonradioactive receptor peptides. The mixtures were incubated at 37 °C for 
90 min in the dark, irradiated with a Mineralight R-52 UV lamp for 3 min as described 
previously (Ji and Ji, 1980), and solubilized in 2% SDS, 100 mM dithiothreitol, and 8 M urea. 
The samples were electrophoresed on 8–12% polyacrylamide gradient gels. Gels were dried 
on filter paper and exposed to an imaging screen overnight, which was scanned on a 
PhosphorImager (Molecular Dynamics).  
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Deglycosylation 
The FSH α and β subunits co-migrate on SDS-PAGE. To separate them on the gel, 
FSH was photoaffinity-labeled and deglycosylated with PNGase F. Enzymatic cleavage was 
done by incubation of the labeled FSH complex with 20 or 50 units of PNGase F (New 
England BioLabs) in 40 µl for 18 h at 37 °C. The samples were solubilized in SDS under the 
reducing condition and electrophoresed on 15% gel containing 9 M urea.  
 
Immunoblot of FSH Subunits 
Separated proteins were blotted onto 0.2-µm nitrocellulose membrane as described 
previously (Towbin et al., 1979). Membranes were treated for 1 h with 5% blocking buffer 
(25 mM Tris-HCl, 1.4 M NaCl, 5% nonfat dry milk, 0.2% sodium azide, 1% Nonidet P-40, 
pH 7.4) and incubated with polyclonal anti-FSH and anti-FSH α and β antibodies (dilution 
1:2000 and 1:3500 each in blocking buffer) for 1 h at room temperature. Membranes were 
washed three times (5 min each) with the blocking buffer and incubated with anti-rabbit 
peroxidase-conjugated IgG (dilution 1:5000 in the blocking buffer) for 1 h at room 
temperature. Membranes were washed three times (5 min each) with the blocking buffer and 
twice (5 min each) with 25 mM Tris-HCl, pH 7.4. Membranes were incubated in staining 
solution (0.05% 3,3'-diaminobenzidine, 0.02% CoCl2, 0.03% H2O2) until bands became 
visible.  
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RESULTS 
 
Activities of the N-terminal Region 
In a first step to check the importance of the N-terminal region of human FSHR, each 
amino acid of the 8SNRVFLCQESKVTEIPSDLPRNAIE33 sequence was individually 
substituted with Ala. This sequence is diverse among the glycoprotein hormone receptors 
(Figure 3.2), although these receptors share a high overall homology and structural similarity 
(Ji et al., 1998). In contrast, the FSHR sequence is highly conserved among species, 
implicating its importance. HEK 293 cells were stably transfected with mutant receptor 
plasmids and selected for stably expressing individual mutant receptors. These cells were 
assayed for 125I-FSH binding and FSH-dependent cAMP induction. The results show that 
some of the Ala substitutions significantly impacted the hormone binding and/or cAMP 
induction. 
Ala substitutions for Ser9, Asn10, Arg11, Val12, Phe13, and Leu14 improved FSH 
binding (Figure 3.3, A and B), FSH-dependent cAMP induction (Figure 3.3.C), or both. The 
Kd values of FSHRN10A, FSHRR11A, and FSHRL14A were lower than the wild type value as 
were the EC50 values of FSHRS9A, FSHRN10A, FSHRV12A, FSHRF13A, and FSHRL14A (see 
tables in Figure 3.3). Ala substitutions for Gln16, Glu17, Lys19, and Val20 did not impact the 
EC50 values and maximal cAMP induction (Figure 3.3.F), and Kd values of the mutants were 
similar to or somewhat higher than the wild type value (Figure 3.3, D and E). In contrast, the 
S18A substitution resulted in a considerably lower EC50 value despite a higher Kd value. 
These results show an improved cAMP induction despite a lower hormone binding affinity 
and suggest an interesting and potentially crucial role of Ser18 in modulating signal generation. 
Ala substitution for Thr21, Glu22, or Ser25 did not significantly impact hormone 
binding or cAMP induction (Figure 3.4). On the other hand, the I23A substitution partially 
impaired the cAMP induction with a 23-fold higher EC50 value and 2.6-fold lower maximal 
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cAMP level. The P24A, D26A, and L27A substitutions completely abrogated hormone 
binding and therefore cAMP induction, suggesting the importance of these residues and this 
region. The P28A, R29A, N30A, A31G, I32A, and E33A substitutions did not dramatically 
impact the Kd and EC50 values or the maximal cAMP production (Figure 3.4). The 
nonbinding mutants were either incapable of binding the hormone or trapped in cells, and 
these possibilities have successfully been tested by assaying hormone binding after 
solubilization of cells in nonionic detergents (Hong et al., 1998; Hong et al., 1997; Rozell et 
al., 1995). The binding assay for receptors solubilized in Nonidet P-40 showed that FSH did 
not bind to any of the C15A, P24A, D26A, and L27A mutants (Figure 3.5.A), indicating that 
they are incapable of hormone binding. However, the result does not necessarily prove the 
surface expression of the nonbinding mutants and nonbinding on the surface. Therefore, the 
cells expressing them were probed with 125I-anti-FSHR antibody. The antibody bound to the 
cells (Figure 3.5.B), indicating the surface expression of the mutants and their inability to 
bind the hormone on the cell surface. These results, taken together, show several distinct 
effects of Ala substitutions as shown in the summary bar graph (Figure 3.6). C15A, P24A, 
D26A, and L27A abolished hormone binding. In contrast to these nonbinding mutations, 
N10A, R11A, and L14A improved hormone binding. On the other hand, I23A impaired 
cAMP induction by dramatically increasing the EC50 value. Remarkably, S9A, V12A, F13A, 
S18A, and I32A reduced the EC50 value by 2–3-fold while maintaining or slightly enhancing 
the maximum cAMP induction level. These results suggested the importance of this region of 
the receptor in hormone binding and cAMP induction and raised a question as to whether this 
region directly interacts with the hormone or indirectly impacts the global structure of the 
receptor. 
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Photoaffinity Labeling of FSH 
To examine the two general possibilities, a peptide mimic corresponding to the 
receptor sequence of 8SNRVFLCQESKVTEIPSDLPRNAIELRFVLTK40 was synthesized, 
FSHR9–40 (Figure 3.7.A). A Tyr residue was attached to the N terminus for radioiodination, 
and the N terminus was acetylated while the C terminus amidated. Phe13 was substituted with 
Bpa for photoaffinity labeling (Kauer et al., 1986). The ketone moiety of the Bpa group can 
be activated with UV at >350 nm and is capable of reacting with unreactive α-CH bonds of 
amino acids (Bayley, 1983; Dorman and Prestwich, 1994; Kauer et al., 1986). To determine 
whether the resulting peptide 125I-FSHR9–40F13Bpa could bind and photoaffinity-label FSH, it 
was incubated with FSH and irradiated with UV for increasing time periods. Samples were 
solubilized in SDS under reducing conditions and then electrophoresed. The autoradiographic 
phosphorimage of the gel (Figure 3.7.B) revealed labeling of the FSH band. The 
autoradiograph suggests that the two subunits of human FSH comigrated. The band was not 
labeled when the sample was not irradiated with UV, indicating the requirement for UV 
irradiation. The extent of the labeling was dependent on the irradiation time, reaching 
maximum labeling after 30-s irradiation. The result shows that the labeling is saturable. The 
hormone was labeled next with increasing concentrations of 125I-FSHR9–40F13Bpa while 
maintaining FSH at a constant concentration (Figure 3.7.C). Conversely, increasing 
concentrations of FSH were labeled with a constant concentration of 125I-FSHR9–40F13Bpa 
(Figure 3.7.D). If the labeling was specific, the concentrations should reach a plateau under 
both conditions. Indeed, the labeling plateaued under both conditions, indicating saturable 
and specific labeling of a substantial portion (>50%) of FSH. Furthermore, the labeling 
should be inhibited by nonradioactive peptide and unmodified wild type peptide. Therefore, 
FSH was incubated with 125I-FSHR9–40F13Bpa in the presence of increasing concentrations of 
wild type peptide and nonradioactive FSHR9–40F13Bpa (Figure 3.7.E). The peptides inhibited 
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the photoaffinity labeling in a dose-dependent manner and eventually blocked the labeling. 
Peptides corresponding to exoloops 1–3, FSHRexo1, FSHRexo2, and FSHRexo3, were also tested. 
FSHRexo2 inhibited the labeling as FSHR9–40 did. In contrast, FSHRexo1 inhibited the labeling 
with a 30-fold less potency. On the other hand, FSHRexo3 failed to block the labeling. 
 
Labeling Specificity 
Although the photoaffinity labeling was specific for FSH, our data do not show the 
biological specificity of the affinity labeling. To address this concern, a constant amount of 
denatured FSH was incubated with increasing concentrations of 125I-FSHR9–40F13Bpa and 
treated with UV. Denatured FSH was not labeled at all despite high concentrations of the 
peptide (Figure 3.8.A). Denatured FSH was not labeled when increasing concentrations of 
denatured FSH were incubated with a constant amount of 125I-FSHR9–40F13Bpa and treated with 
UV (Figure 3.8.B). When FSH was denatured by boiling in 8 M urea for 30 min, it did not 
bind to FSHR and induce cAMP production. To test whether the denatured FSH remained in 
solution, the mixture of radioactively labeled FSH and unlabeled FSH was denatured and 
varying volumes of the mixture were transferred to other tubes and the radioactivity was 
counted. The transfer was quantitative with 99–100% efficiency, indicating that denatured 
FSH was present in the photoaffinity-labeling tube. These results indicate the specificity of 
the affinity labeling for biologically active FSH. To determine the labeling specificity, 
luteinizing hormone (LH), thyroid-stimulating hormone (TSH), growth hormone, 
phospholipase A, and urokinase were subjected to photoaffinity labeling with 125I-FSHR9–
40F13Bpa (Figure 3.8.C). None of them was labeled. If 125I-FSHR9–40Bpa13 specifically binds to 
FSH and labels it as indicated by the results, the peptide is expected to inhibit the in vivo 
binding of FSH to the receptor on intact cells. Indeed, FSHR9–40Bpa13 and FSHR9–40 inhibited 
125I-FSH binding to the receptor (Figure 3.8.D). 
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Labeling of FSH β Subunit 
Because the two subunits of purified human FSH appeared to comigrate on SDS-
PAGE, it was unclear which of the subunits was labeled. To resolve the subunits, FSH was 
deglycosylated with PNGase F and electrophoresed (Figure 3.9.A, lane 2). The two subunits 
were clearly separated into two distinct bands. Because the β subunit is larger than the α 
subunit, the upper band is probably the β subunit. To conclusively determine the identity of 
the upper band, deglycosylated FSH was electrophoresed, the gel was blotted on 
nitrocellulose membrane, and the membrane was probed with anti-FSH α and anti-FSH β 
antibodies. Anti-FSH α antibody conspicuously labeled the lower band, whereas the anti-
FSH β antibody recognized primarily the upper band and faintly the lower band (Figure 3.9, 
A and B). These results show that the lower band represents the FSH α subunit, whereas the 
upper band is the FSH β subunit, indicating that FSH β was labeled. To compare this labeling 
of FSH β with the N-terminal peptide, the exoloop 3 peptide, FSHRexo3, was used for labeling 
FSH. The peptide was derivatized with a UV-activable reagent, ABG, and radioiodinated. 
The resulting 125I-ABG-FSHRexo3 was incubated with FSH, irradiated with UV, 
deglycosylated, and electrophoresed. The labeled FSH subunit appeared in the lower band, 
indicating the labeling of the FSH α subunit (Figure 3.9.C) as reported previously (Sohn et al., 
2002). 
The labeling of FSH β by 125I-FSHR9–40F13Bpa contrasts the labeling of the FSH α 
subunit by the FSHR exoloop 3 peptide. If this contrasting labeling is specific and reflects the 
true interaction between FSH and the receptor, some of the peptides representing parts of the 
α subunit sequence might inhibit the labeling. Particularly, if some of the α peptides block 
the labeling of the α subunit but not the β subunit, the result would support the selective 
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labeling results and show labeling specificity. Four peptides, α1–15, α 26–46, α 61–75, and α 81–92 
were tested, and none of them inhibited the labeling of the FSH β subunit by 125I-FSHR9–
40F13Bpa (Figure 3.10.A). In contrast, the labeling of the FSH α subunit by 125I-ABG-FSHRexo3 
was blocked by α 26–46 and somewhat by α 61–75 (Figure 3.10.B). α 1–15 and α 81–92 Peptides 
failed to block the labeling. These results support the differential labeling and its selectivity 
and validity. 
 
 
DISCUSSION 
The Ala-scanning results indicate that the Ser9-Glu33 sequence of the FSH receptor is 
important for surface expression, hormone binding, and signal generation. The photoaffinity-
labeling results show that FSHR9–40F13Bpa photoaffinity labels FSH but not LH, TSH, growth 
hormone, phospholipase A, and urokinase. The labeling is saturable and dependent on the 
concentrations of FSH and derivatized 125I-FSHR9–40, UV activation, and UV exposure time. 
125I-FSHR9–40F13Bpa photoaffinity labels bioactive FSH but not denatured hormone, and the 
labeling is blocked by nonderivatized wild type peptide and nonradioactive FSHR9–40F13Bpa. 
The labeling specificity is further underscored by the fact that it labeled the β subunit but not 
the α subunit. These results suggest that the N-terminal region of the FSH receptor is in close 
proximity to FSH, probably interacting with the hormone. This conclusion is consistent with 
the previous reports that some residues of the region are important for hormone binding and 
receptor trafficking (Bradbury et al., 1997; Nechamen and Dias, 2000; Nechamen and Dias, 
2003) and that the similar region of the LH receptor interacts with human chorionic 
gonadotropin (Hong et al., 1998; Phang et al., 1998).  
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In contrast to the labeling of the β subunit by the N-terminal peptide, the exoloop 3 
peptide labeled the α subunit. The significance of these contrasting results is 2-fold. First, it 
supports the validity and specificity of the photoaffinity labeling. Second, it provides the 
crucial information on the overall arrangement of the ternary complex involving the 
exodomain, FSH, and endodomain. The results suggest that the β subunit is near the N-
terminal region of the exodomain, whereas the α subunit is close to the exoloops of the 
endodomain. These are consistent with the previous reports that only the αβ dimer is capable 
of high affinity binding to receptors and inducing biological responses (Pierce and Parson, 
1981; Roche and Ryan, 1985). Interestingly, all glycoprotein hormones utilize similar if not 
identical signal pathways consisting of adenylyl cyclase and phospholipase Cβ. Therefore, the 
α subunit has been implicated in the signal generation (Pierce and Parson, 1981). 
Based on these results, it is now possible to project the hormone interacting with both 
the exodomain and endodomain. Furthermore, they suggest that the hormone is probably in a 
vertically tilted position with respect to LRRs of the exodomain and the endodomain. To help 
visualize the arrangement and facilitate modeling of the ternary complex, one of several 
possible models is presented in Figure 3.1.E. The model suggests that parts of the α subunit 
might interact with LRRs and, conversely, that some parts of the β subunit may be close to 
the exoloops. Such interactions could be probed by strategically attaching a photoactivable 
group at appropriate positions of the hormone subunits and/or using a reagent that can reach 
farther than ABG and Bpa. These two reagents can reach 10 and 7 Å, respectively. Other 
additional information will also be necessary to more precisely define the ternary structure. 
For example, the crystal structure of FSH shown in the model does not likely represent its 
structure in the ternary complex, because the gonadotropin undergoes conformational 
changes, particularly the interaction between the two subunits upon the initial interaction with 
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the receptor (Ji et al., 1995a). These conclusions are consistent with observations that the 
original quaternary structure of unbound hormone dimers is not essential for hormone action 
(Garcia-Campayo et al., 2002; Jackson et al., 1999). 
The results that Ala substitution for some N-terminal residues improved hormone 
binding, cAMP induction or both suggest an interesting possibility that this region is involved 
in modulating not only hormone binding but also signal generation. The most dramatic 
improvement is seen in the S18A substitution, which improved the EC50 value of cAMP 
induction by 3-fold as compared with the wild type value. Additionally, the maximum level 
of cAMP production only slightly increased. These observations indicate that the affinity and 
maximum level of cAMP induction are distinctly regulated. They suggest that FSH activates 
FSHRS18A more effectively than the wild type receptor does, which in turn results in better 
activation of the G protein. It will be interesting to see whether the number of activated G 
protein molecules is the limiting factor. The improved EC50 is not related to the hormone 
binding affinity because the binding affinity of the mutant is somewhat less than the wild type 
affinity. These novel observations suggest an intriguing possibility that FSHRS18A is more 
sensitive to hormone binding and is capable of activating the G protein with higher affinity 
without significantly impacting the level of activation. Because the exodomain is likely to 
modulate the endodomain to generate hormone signals at the exoloops (Dufau, 1998; Ji et al., 
1998; Ji et al., 1995b; Nishi et al., 2002; Zeng et al., 2001), a simple possibility is that the 
affinity of the modulation at the interface between the exodomain and exoloops is improved 
in FSHRS18A. Several other Ala substitutions, S9A, V12A, and F13A, also showed similar yet 
less dramatic results.  
In conclusion, the evidence is presented that in the ternary 
exodomain/FSH/endodomain complex, FSH is vertically oriented with the β subunit close to 
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the N-terminal region and the α tip projecting toward the exoloop 3. This is consistent with 
the recent report of the crystal structure of FSH/FSHR complex (Fan and Hendrickson, 
2005). 
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Figure 3.1 Structure of FSH and receptor.  
A, crystal structure of FSH, the α subunit in red and β subunit in green.  
B, a schematic drawing of FSHR with two distinct domains, exodomain and endodomain. C, 
a schematic drawing of FSH interacting horizontally with LRRs of the exodomain. Note that 
the orientation of the α and β subunits could be switched if the hormone is horizontally 
flipped. D, a schematic drawing of FSH interacting vertically with LRRs of the exodomain. 
Note that the orientation of the α and β subunits could be switched if the hormone is 
vertically flipped. E, a hypothetical interaction of FSH α and β with the LRRs of the 
exodomain and the exoloops of the endodomain. The FSH β subunit is close to the N-
terminal region of the exodomain, whereas the FSH α tip is projected toward the exoloops of 
the endodomain. The tilted orientation of FSH is based on this study. 
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Figure 3.2 Comparison of the primary sequence of the first 34 residues of the 
glycoprotein hormone receptors.  
The FSH receptor sequences of various species were compared with the corresponding 
sequences of the human LH receptor and TSH receptor. Cys15, Ser18, Pro24, Asp26, and Leu27 
of FSHR are conserved among the species. 
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Figure 3.3 Ala substitutions for Ser9-Val20. A–F, residues from Ser9 to Val20 of the FSH 
receptor were individually substituted with Ala, and the resulting mutant receptors were 
stably expressed in HEK 293 cells. Intact cells were used for 125I-FSH binding in the presence 
of increasing concentrations of unlabeled FSH (A and D) and for cAMP production (C and 
F). The competitive inhibition data (A and D) were converted to Scatchard plot (B and E). 
Experiments were repeated 4–6 times in duplicate, and the means ± S.D. were calculated. NS, 
not significant. 
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Figure 3.4 Ala substitutions for Thr21-Glu33.  A–F, residues from Thr21 to Glu33 of the FSH 
receptor were individually substituted with Ala, and the resulting mutant receptors were 
expressed in HEK 293 cells and assayed as described in the legend to Figure 3.3. 
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Figure 3.5 Hormone binding in solution and anti-FSHR antibody binding to intact cells.  
A, cells individually transfected with the C15A, P24A, D26A, or L27A mutant receptor were 
solubilized in Nonidet P-40 and assayed for 125I-FSH binding as described under 
"Experimental Procedures." B, intact cells were also probed with 125I-labeled monoclonal 
anti-FSHR 106.105 antibody for the surface expression of the nonbinding mutants. 
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Figure 3.6 Comparison of Ala substitution mutations. To easily compare the activities of 
the wild type and mutant receptors, the ratios of Kd wild type mutant, EC50 wild type mutant, 
and maximum cAMP mutant wild type were presented in a bar graph. 
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Figure 3.7 Photoaffinity labeling of FSH with photoactivable FSHR9–40F13Bpa.  
The FSH receptor peptide corresponding to the sequence Ser9-Lys40 (FSHR9–40) was 
synthesized with a Tyr at the N terminus for radioiodination and Bpa at the position of Phe13 
for photoaffinity labeling (A). The peptide was radioiodinated, and the resulting 125I-FSHR9–
40F13Bpa was incubated with FSH and irradiated with UV. B, the sample was irradiated with 
UV for increasing time periods from 0 to 150 s, solubilized in SDS under the reducing 
condition, and electrophoresed on polyacrylamide gel. After drying gels, they were exposed 
to a phosphorimaging screen and scanned on a PhosphorImager. The peptide appeared as the 
lower band, and the FSH α and FSH β subunits comigrated and appeared in the upper band. 
The intensity of each band in a gel lane was measured, and the percentage of the labeled FSH 
band in a gel lane was calculated based on the total intensity of a gel lane and presented in the 
bar graph above the autoradiograph. C, increasing amounts of 125I-FSHR9–40F13Bpa from 0 to 
3.7 µM were incubated with a constant amount (0.1 µM) of FSH and photolyzed for 60 s. The 
samples were processed as described above. D, increasing amounts of FSH from 0 to 0.2 µM 
were incubated with a constant amount (3.1 µM) of 125I-FSHR9–40F13Bpa.  
E, FSH (80 nM) was incubated with 3 µM 125I-FSHR9–40F13Bpa in the presence of increasing 
concentrations of unlabeled FSHR peptides, FSHR9–40, FSHR9–40F13Bpa, exoloop 1 peptide 
(FSHRexo1), exoloop 2 peptide (FSHRexo2), and exoloop 3 peptide (FSHRexo3). The samples 
were irradiated and processed as described in B. 
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Figure 3.8  Photoaffinity labeling of denatured FSH and other glycoproteins.  
A, increasing concentrations of 125I-FSHR9–40F13Bpa were incubated with 80 nM denatured FSH, 
irradiated with UV, and processed as described in the legend to Figure 3.7. FSH was 
denatured by boiling in 8 M urea for 30 min. B, a constant amount of 125I-FSHR9–40F13Bpa was 
incubated with increasing concentrations of denatured FSH, treated with UV, and processed. 
C, a constant amount of 125I-FSHR9–40F13Bpa was incubated with 5 nM each of FSH, 
phospholipase A (PLA), urokinase, growth hormone (GH), LH, or TSH, treated with UV, and 
processed as described in the legend to Figure 3.7. D, cells stably expressing FSHR were 
incubated with 125I-FSH and washed as described in Figure 3.3 but in the presence of 
increasing concentrations of FSHR9–40 or FSHR9–40F13Bpa. Cells were washed three times and 
counted for the bound radioactivity. 
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Figure 3.9  Immunoblot of FSH α and β subunit bands.  A, FSH was treated with PNGase 
F, solubilized in SDS under the reducing condition, and electrophoresed along with 
nondeglycosylated FSH. Gel lanes were either stained with Coomassie Brilliant Blue (CBB) 
or blotted and stained with anti-FSH, anti-FSH α, or anti-FSH β antibodies. B, FSH was 
incubated with increasing concentrations of 125I-FSHR9–40F13Bpa, treated with UV, 
deglycosylated with PNGase F, solubilized, and electrophoresed along with 125I-FSH. C, the 
peptide corresponding to exoloop 3 (FSHRexo3) was derivatized with a UV-activable reagent, 
ABG, and radioiodinated. The resulting 125I-ABG-FSHRexo3 was incubated with FSH, treated 
with UV, deglycosylated with PNGase F, solubilized, and electrophoresed (E3). E3 was 
compared with FSH labeled with 125I-FSHR9–40F13Bpa (N). 
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Figure 3.10  Inhibition of photoaffinity labeling of FSH.  Peptides corresponding to the α 
subunit sequences, 1–15, 26–46, 61–75 and 81–92, were synthesized. FSH was incubated 
with either 125I-FSHR9–40F13Bpa or 125I-ABG-FSHRexo3 in the presence of an excess amount of 
α1–15, α26–46, α61–75, or α81–92. The samples were irradiated with UV and processed, and the 
percentage of the labeled FSH was calculated above the autoradiographs as described in 
Figure 3.7. 
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